KRAS and neoplasm: Stratification by tumor subtype revealed KRAS mutations in 24.9% (n = 554/2227) of patients with IHC, 32.2% (n = 513/1593) of those with EHC, and 9.4% (n = 131/1388) of those with GB (Figure 1B).